Advertisement

Lymphoproliferative Disorders

  • Nages Nagaratnam
  • Kujan Nagaratnam
  • Gary Cheuk
Reference work entry

Abstract

This review discusses the lymphoproliferative disorders, their prevalence and clinical management. Chronic lymphocytic leukaemia (CLL) is derived from mature B lymphocytes and is characterised by a progressive accumulation of lymphocytes in the blood, bone marrow and lymphatic tissues. CLL is a disease of the elderly. Antileukaemic therapy is frequently unnecessary in uncomplicated early disease. Non-Hodgkin’s lymphoma includes a diverse group of haematological causes which embraces any lymphoma other than Hodgkin’s lymphoma and by the absence of Reed-Sternberg cells. Hodgkin’s lymphoma (HL) is a malignant tumour of the lymphatic tissues and weakens the immune system.

Keywords

Lymphoproliferative disorders Chronic lymphocytic leukaemia Non-Hodgkin’s lymphoma Hodgkin’s lymphoma Reed-Sternberg cells 

References

  1. 1.
    Klein U, Dalla-Favera R. New insights into the pathogenesis of chronic lymphocytic leukaemia. Semin Cancer Biol. 2010 20(6):377–83.CrossRefPubMedGoogle Scholar
  2. 2.
    Catovsky D, Fooks J, Richards S. Prognostic factors in chronic lymphatic leukaemia: the importance of age, sex and response to treatment in survival: a report from MRC CLL. Brit J Haemat. 1989;72(2) 141–149.CrossRefPubMedGoogle Scholar
  3. 3.
    Rozman C, Montserrat E. Current concepts: Chronic lymphocytic leukaemia . NEJM. 1995;333:1052–1057.CrossRefPubMedGoogle Scholar
  4. 4.
    Linet MS. Blattner WA. The epidemiology of chronic lymphocytic leukaemia. In Pollack A, Catovsky D eds Chronic Lymphocytic Leukaemia Switzerland: Hardwood Academic Publishers 1988: 11.Google Scholar
  5. 5.
    Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics CA Cancer J Clin. 1998;48:6–29.CrossRefPubMedGoogle Scholar
  6. 6.
    Linet MS, Cartwright RA. Chronic Lymphocytic leukaemia: epidemiology and etiologic findings. Nouv Rev Fr Haematol. 1988;30:353–357.Google Scholar
  7. 7.
    Kalil N, Cheson BD. Chronic lymphocytic leukaemia. The Oncologist. 1999;4 (5):S352–369.Google Scholar
  8. 8.
    Anaissie EJ, Kotoyiannis DP, O’Brien S, Kantarjian H, Robertson L, Lerner S, et al. Infections in patients with chronic lymphatic leukaemia treated with fludarabine. Ann Int Med. 1998;129(7):559–566.CrossRefPubMedGoogle Scholar
  9. 9.
    Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F, et al. Autoimmune haemolytic anaemia in chronic lymphocytic leukaemia: clinical, therapeutic and prognostic features. Blood. 2000;95(9):2786–2792.PubMedGoogle Scholar
  10. 10.
    Engelfriet CP, Overbeeke MAM, B Von den Borne AE. Autoimmune haemolytic anaemia. Semin Hematol. 1992;29:3–12.PubMedGoogle Scholar
  11. 11.
    Tabhara IA. Hemolytic anaemias: diagnosis and management. Med Clin North Am. 1992;76:649–668.CrossRefGoogle Scholar
  12. 12.
    Cheson BD, Bennett IM, Kay N, Keating MJ, O’Brien S, Rai KR. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukaemia: revised guidelines for diagnosis and treatment. Blood. 1996;12:4990–4997.Google Scholar
  13. 13.
    Chronic lymphocytic leukaemia: recommendation for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukaemia. Ann Int Med. 1989;110(3):236–238.Google Scholar
  14. 14.
    Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pastremack SS. Clinical staging of chronic lymphocytic leukaemia. Blood. 1975;46:219.PubMedGoogle Scholar
  15. 15.
    Gibson J, Iland HJ, Larsen SR, Brown CMS, Joshua DE. Leukaemias into the 21st century-part 2: the chronic leukaemia. Int Med J. 2013; 43: 484–494.CrossRefGoogle Scholar
  16. 16.
    Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer T, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphatic leukaemia: a randomised, open label, phase 3 trial. Lancet. 2010;276:1164–74.Google Scholar
  17. 17.
    Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. NEJM. 2014;370:1101–10.CrossRefPubMedGoogle Scholar
  18. 18.
    Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomdedeu J, et al. Allogenic stem-cell transplants may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukaemia. J Clin Oncol. 2005;23(15):3433–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Rolland-Portal I, Tazi MA, Milan C, Couillaut C, Carli PM. Non-Hodgkins lymphoma: time trends for incidence and survival in Cote- D’O r France. Int J Epidemiol. 1997;26(5): 945–952.CrossRefPubMedGoogle Scholar
  20. 20.
    Young GAR, Iland HJ. Clinical perspectives in lymphoma. Int Med J. 2007;37:478–484.CrossRefGoogle Scholar
  21. 21.
    Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs. 2003;63(3): 803–43.CrossRefPubMedGoogle Scholar
  22. 22.
    Pfreundschuh M, Trumper L, Osterburg A, Pettengell R, Tmery M, Imrie K, et al. CHOP like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in younger patients with good prognosis diffuse large B-cell lymphoma: a randomized controlled trial by Mabthera International Trial (MinT) Group. Lancet Oncol. 2006;7:379–391.CrossRefPubMedGoogle Scholar
  23. 23.
    Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bonabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groups d’etude des Lymphomes d’Adulte. J Clin Oncol. 2005; 23:4117–26.CrossRefPubMedGoogle Scholar
  24. 24.
    SEER. Stat Fact Sheet: Hodgkins lymphoma. National Cancer Institute. http://seer.cancer.gov/statfacts/htm/hodg.html. accessed 16 February 2015.
  25. 25.
    Poppema S. Immunobiology and pathophysiology of Hodgkin’s lymphoma. ASH Education Book. 2005;1:231–238. http://asheducationbook.hematologylibrary.org/content/2005/1/231. full accessed on 23/05/2012.
  26. 26.
    Schwarzer R, Jundt F. Notch and NF-kB signalling pathways in the biology of classical Hodgkin lymphoma. Curr Mol Med 2011;11(3):26–45.CrossRefGoogle Scholar
  27. 27.
    Harris NL. Hodgkin’s disease: classification and differential diagnosis. Mod Pathol 1999;12(2):159–7.PubMedGoogle Scholar
  28. 28.
    Foss HD, Msarafioti T, Stein H. Hodgkin lymphoma. Classification and pathogenesis. Pathologe. 2000;21(2):113–23.CrossRefPubMedGoogle Scholar
  29. 29.
    Re D, Kuppers R, Diehl V. Molecular pathogenesis of Hodgkin’s lymphoma. J Clin Oncol. 2005;23(26):6379–86.CrossRefPubMedGoogle Scholar
  30. 30.
    Farrell K, Jarrett RF. The molecular pathogenesis of Hodgkin lymphoma. Histopathology. 2011;58(1):15025.CrossRefGoogle Scholar
  31. 31.
    Gruss HJ, Kadin ME. Pathophysiology of Hodgkin’s disease: functional and molecular aspects. Baillieres Clin Haematol. 1996;9(3): 417–46.CrossRefPubMedGoogle Scholar
  32. 32.
    Brauninger A, Schmitz R, Bechtel D, Renne C, Hansmann ML, Kuppers R. Molecular biology of Hodgkin and Reed/Sternberg cells in Hodgkin’s lymphoma. In J Cancer. 2006;118(8):1853–61.Google Scholar
  33. 33.
    Hardell L, Axelson O. Environmental and occupational aspects on the etiology of non-Hodgkin’s lymphoma.Oncol Res. 1998;10(1):1–5.PubMedGoogle Scholar
  34. 34.
    Mesa R, Miller CB, Thyme M, Mangan J, Goldberg S, Fazal S, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity, the MPN Landmark Survey. BMC Cancer. 2026;16:67.  https://doi.org/10.1186/s12885-016-2208-2.
  35. 35.
    Hameed A, Brady JJ, Dowling P, Clynes M, O’Gorman P. Bone disease in multiple myeloma: Pathophysiology and management. Cancer Growth and Metastasis. 2014;7:33–42.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Allart-Vorelli P, Porro B, Baguet F, Michel A, Cosson-Glie F. Haematological cancer and quality of life: a systematc literature review. Blood Cancer J. 2015;5,e305;  https://doi.org/10.1038/bcj.2015.29.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Hassan M, Abedi-Vahegerd M. Haematological malignancies in elderly patients. Haematologica. 2014;99:1124–1127.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Nargaard M, Larsson H, Pedersen G, Schenheyder HC, Rothman KJ, Serensen HY. Short-term mortality of bacteraemia in elderly patients with haematological malignancies. Br J Haematol. 2006;132:(9):25–31.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Nages Nagaratnam
    • 1
  • Kujan Nagaratnam
    • 1
  • Gary Cheuk
    • 2
  1. 1.The University of SydneyWestmead Clinical SchoolWestmeadAustralia
  2. 2.Rehabilitation and Aged Care ServiceBlacktown-Mt Druitt HospitalMount DruittAustralia

Personalised recommendations